Home › Funds › Morgan Stanley › PCVX
Morgan Stanley position in PCVX
VAXCYTE INC · Health Care
Latest position (Q2 2026)797.72K sh
Reported value held$46.37M
Portfolio Weight0.00%
First reportedQ3 2021
Last changeAdd
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2021 | 38.08K | $966.00K | New |
| Q4 2021 | 57.84K | $1.38M | Add |
| Q1 2022 | 88.93K | $2.15M | Add |
| Q2 2022 | 137.67K | $3.00M | Add |
| Q3 2022 | 42.53K | $1.02M | Reduce |
| Q4 2022 | 168.12K | $8.06M | Add |
| Q1 2023 | 170.62K | $6.39M | Add |
| Q2 2023 | 425.09K | $21.23M | Add |
| Q3 2023 | 409.55K | $20.88M | Reduce |
| Q4 2023 | 537.37K | $33.75M | Add |
| Q1 2024 | 490.45K | $33.50M | Reduce |
| Q2 2024 | 409.69K | $30.94M | Reduce |
| Q3 2024 | 694.87K | $79.40M | Add |
| Q4 2024 | 693.33K | $56.76M | Hold |
| Q1 2025 | 606.95K | $22.92M | Reduce |
| Q2 2025 | 841.92K | $27.37M | Add |
| Q3 2025 | 784.48K | $28.26M | Reduce |
| Q4 2025 | 835.39K | $38.54M | Add |
| Q1 2026 | 735.91K | $42.76M | Reduce |
| Q2 2026 | 797.72K | $46.37M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding PCVX
- Fidelity Management & Research (FMR) 20.85M sh · $1.21B · Q2 2026
- Janus Henderson Group 16.58M sh · $960.23M · Q1 2026
- BlackRock Inc 12.07M sh · $701.52M · Q2 2026
- Vanguard Group 12.19M sh · $562.63M · Q4 2025
- Wellington Management Group 7.00M sh · $407.00M · Q2 2026
- Geode Capital Management 3.46M sh · $201.13M · Q2 2026
- D. E. Shaw & Co 1.90M sh · $110.56M · Q2 2026
- Maverick Capital 1.61M sh · $93.78M · Q2 2026
- Charles Schwab Investment Management 1.46M sh · $85.15M · Q2 2026
- Goldman Sachs Group 1.38M sh · $79.98M · Q2 2026
- Northern Trust Corp 1.28M sh · $74.42M · Q2 2026
- Norges Bank Investment Management 1.25M sh · $72.42M · Q2 2026